

FAX TRANSMISSION**OFFICIAL****DATE:** June 16, 2003**PTO IDENTIFIER:** Application Number 09/743,479 Conf. #2847
Patent Number**Inventor:** Penny Corrigan**MESSAGE TO:** I. Ghali**FAX RECEIVED****FAX NUMBER:** (703) 872-9307

JUN 17 2003

GROUP 1600**FROM:** CONNOLLY BOVE LODGE & HUTZ LLP
Morris Liss**PHONE:** (202) 331-7111**Attorney Dkt. #:** 21854-00016-US**PAGES (Including Cover Sheet):** 7**CONTENTS:**

If your receipt of this transmission is in error, please notify this firm immediately by collect call to (202) 331-7111 and send the original transmission to us by return mail at the address below.

CONNOLLY BOVE LODGE & HUTZ LLP
1990 M Street, N.W., Suite 800, Washington, DC 20036-3425
Telephone: (202) 331-7111 **Facsimile:** (202) 293-6229

PTO/SB/97 (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Certificate of Transmission Under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States
Patent and Trademark Office

on June 16, 2003
Date


Signature

Donald S. Prater
Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Two Month Request for Extension of Time Under 37 CFR 1.136(a);
Request for Reconsideration; and
Charge \$410.00 to deposit account 22-0185.

9/ Reg for Recons
Docket No.: 21854-00016-US
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Penny Corrigan

Conf. No.

Application No.: 09/743,479

Group Art Unit: 1615

Filed: January 10, 2001

Examiner: I. Ghali

For: BIOCIDAL PACKAGING SYSTEM

REQUEST FOR RECONSIDERATION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action dated April 14, 2003, the Examiner is requested to consider the following remarks which should clarify the patentability of the remaining claims 2-6.

REMARKS

Claim 2 was rejected under 35 U.S.C. § 102(b) as being anticipated by WO 95/06690 ('670). The Office Action asserts that this reference discloses a film containing a polymer blend comprising vinyl acetate or vinyl alcohol, ethylene glycol and antifungals. The antifungals referred to by the Examiner are disclosed in the reference on page 6, line 30 through page 7, line 5. However, the reference is quite clear that the antifungal is a "biological active substance having curative or therapeutic value for human beings or non-human beings." In other words, the broad recitation of an antifungal need not relate to the claimed antifungal agent activated by the presence of moisture. As a matter of fact, therapeutic antifungals are typically organic compounds that exhibit

271358